Pharma's R&D Heartburn Spells Opportunity for GI-Focused Biotechs

By Christopher Morrison, IN VIVO 11/1/2007

• Feature Articles
• Word Count: 5331
• Art # 2007800170

Executive Summary

IN VIVO -- Some Big Pharma have looked at the risk-reward equation for gastrointestinal R&D and they have opted out. But GI still represents a massive opportunity for Big Pharma, both in terms of its traditional primary care strengths and more recent forays into specialist medicine. This combination should open up new doors for GI-focused biotech players, several of which feel they can succeed where pharma has failed in tricky areas like IBS, with next generation drugs. Others have hitched their stars to commercially unvalidated targets, exploring new and potentially lucrative mechanisms of action.

For $125, purchase this 5331-word article as a PDF, and receive immediate delivery via email. View a complete sample article.
Questions? Call Toll Free (800) 332-2181 or (908) 547-2159.

100% Satisfaction Guarantee